CureVac stock holds near USD 3 as pipeline focus continues

Published on 09/23/2026 at 00:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CureVac stock closed at USD 3.00 on September 22, 2026, while its 52-week range spans USD 2.10 to USD 5.40. The company reported H1 revenue of EUR 12.4 million.

CVAC, NL0015436031, Illustration mit AI erstellt.

CureVac N.V. (ISIN NL0015436031) stock closed at USD 3.00 on September 22, 2026, on Nasdaq, with the latest session showing a 1.6 percent decline from the prior close. The 52-week range of USD 2.10 to USD 5.40 places the share below its yearly high as investors assess the biotechnology company's development pipeline.

Pipeline progress drives valuation

CureVac reported revenue of EUR 12.4 million for the first half of 2026, compared with EUR 18.7 million in the first half of 2025, a year-over-year decline of 33.7 percent. The period also included a net loss of EUR 62.8 million, compared with a net loss of EUR 55.4 million in the prior-year period.

The comparison matters because revenue alone does not describe the investment case for a clinical-stage biotechnology company. Cash consumption, development milestones and partner funding determine how long the pipeline can advance before additional financing becomes necessary.

Cash use remains a key measure

For the second quarter of 2026, CureVac recorded operating expenses of EUR 38.6 million and cash and cash equivalents of EUR 110.2 million at June 30, 2026. Cash was therefore 18.4 percent lower than the EUR 134.9 million reported at December 31, 2025.

The figures make the operating comparison more important than the share price alone. A 33.7 percent revenue decline combined with an 18.4 percent reduction in cash leaves execution and financing discipline as central valuation variables for the remainder of fiscal year 2026.

Stock remains below yearly high

The Nasdaq reference price was USD 3.00 as of September 22, 2026, while the session change was minus 1.6 percent. The latest level is USD 2.40 below the 52-week high of USD 5.40 and USD 0.90 above the 52-week low of USD 2.10.